Details for New Drug Application (NDA): 091215

NDA 091215 describes EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, which is a drug marketed by Aurobindo Pharma, Cipla, Hetero Labs Ltd V, Laurus, Macleods Pharms Ltd, and Teva Pharms Usa, and is included in six NDAs. It is available from seven suppliers. Additional details are available on the EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE profile page.

The generic ingredient in EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE is efavirenz; emtricitabine; tenofovir disoproxil fumarate. There are twenty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the efavirenz; emtricitabine; tenofovir disoproxil fumarate profile page.

Summary for 091215

Tradename:	EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE
Applicant:	Teva Pharms Usa
Ingredient:	efavirenz; emtricitabine; tenofovir disoproxil fumarate
Patents:	0

Pharmacology for NDA: 091215

Mechanism of Action

Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C9 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A4 Inhibitors Non-Nucleoside Reverse Transcriptase Inhibitors Nucleoside Reverse Transcriptase Inhibitors

Suppliers and Packaging for NDA: 091215

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	091215	ANDA	Teva Pharmaceuticals USA, Inc.	0093-5234	0093-5234-56	30 TABLET, FILM COATED in 1 BOTTLE (0093-5234-56)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	600MG;200MG;300MG
Approval Date:	Nov 9, 2018	TE:	AB	RLD:	No

Complete Access Available with Subscription